Cagrilintide and Semaglutide are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two hormone systems, one appetite question
Most of the headline weight-research peptides — Semaglutide, Tirzepatide, Retatrutide — belong to a single family: the incretins, gut hormones released after eating. Cagrilintide does not. It is an amylin analogue, working through a separate neuroendocrine system entirely. That single fact is what makes the "cagrilintide vs semaglutide" comparison genuinely interesting: these are not two versions of the same idea but two different mechanisms acting on partially non-overlapping satiety circuits. The natural consequence — and the reason both molecules matter so much in current research — is that they can be combined. Put them side by side first, then look at why they add up.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Class / peptide type | Amylin analogue (AM833) | GLP-1 receptor agonist (incretin) |
| Primary target | Amylin / calcitonin receptors (AMY₁−₃) | GLP-1 receptor (GLP-1R) |
| Structure note | C20 fatty-diacid conjugate | C18 fatty-diacid conjugate · ~4,114 Da |
| Approx. half-life | ~7–8 days | ~7 days (~165 h) |
| Main research focus | Satiety / weight management | Weight, glycaemic control, CV outcomes |
| Typical pairing | With Semaglutide (CagriSema) | Reference standard; paired in CagriSema |
| Regulatory status | Investigational (Phase 3 as CagriSema) | FDA-approved (clinical formulations) |
Cagrilintide: the amylin arm
Cagrilintide (developer code AM833, Novo Nordisk) is a synthetic, acylated long-acting analogue of amylin — the islet amyloid polypeptide co-secreted with insulin from pancreatic β-cells. It is an agonist of the amylin/calcitonin receptors (the AMY₁, AMY₂ and AMY₃ subtypes), a receptor system entirely separate from the incretin receptors. Its principal sites of action lie in the brainstem — the area postrema and dorsal vagal complex — where amylin signalling drives satiety and slows gastric emptying.
A C20 fatty-diacid acylation promotes reversible albumin binding and stretches its half-life to roughly seven to eight days, supporting a once-weekly research schedule. In a Phase 1b combination trial, cagrilintide added to semaglutide produced substantially greater weight reduction than semaglutide alone; monotherapy dose-finding reached dose-dependent weight loss more modest than the combination. As of 2026 it remains an investigational compound — supplied only as a research reagent, not an approved medicine. Researchers can buy Cagrilintide UK in two strengths, each HPLC-tested to ≥99% purity with a Certificate of Analysis. Its full profile lives on the Cagrilintide knowledgebase page.
Semaglutide: the incretin benchmark
Semaglutide (Novo Nordisk; marketed clinically as Ozempic, Wegovy and Rybelsus) is the most extensively studied molecule in the incretin class. It is a selective, long-acting GLP-1 receptor agonist — an analogue of native GLP-1, conjugated to a C18 fatty-diacid chain that gives it a ~7-day half-life and a once-weekly cadence. Activating a single receptor expressed across the pancreas, brain appetite centres and gut, it produces a coordinated response: appetite suppression, glucose-dependent insulin secretion and slowed gastric emptying.
Its distinguishing feature is depth of evidence. In the Phase 3 STEP-1 obesity trial it produced a mean body-weight reduction well into double digits versus placebo, and in the SELECT cardiovascular-outcomes trial it reduced major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes — a hard-endpoint result no other incretin compound had reached at the time. For research purposes it is the reference standard against which newer agonists are benchmarked. RS Bio Labs supplies research-grade material in four strengths; see buy Semaglutide UK for live pricing, and the Semaglutide knowledgebase page for the full profile.
What the differences mean in a research context
Read across the table and the pattern is not "which is stronger" but "which does what". The two compounds have nearly identical half-lives and share the same once-weekly rhythm and albumin-binding design principle — but they engage different receptors on different pathways. Cagrilintide acts predominantly through the brainstem amylin circuitry; Semaglutide recruits the hypothalamic and vagal circuits of GLP-1 biology. Because those pathways only partially overlap, agonising both at once is expected to produce a larger appetite-suppressing effect than either alone.
That is the entire rationale behind CagriSema — the fixed research combination of cagrilintide with semaglutide 2.4 mg. In the Phase 1b study the combination outperformed semaglutide monotherapy, and a later Phase 2 trial in type 2 diabetes found CagriSema superior to either component on its own. The programme advanced into the pivotal Phase 3 REDEFINE obesity trials, making it one of the most closely watched late-stage weight-management combinations in metabolic science. So the honest framing of "cagrilintide vs semaglutide" is that it is often really a question about cagrilintide plus semaglutide: two mechanisms stacked rather than one chosen over the other.
The differences that remain are about maturity and role. Semaglutide carries an approved, deep clinical dataset and serves as the fixed reference arm; Cagrilintide is investigational, its profile still being written, and its defining value is that it contributes a mechanism the incretins do not supply. For researchers modelling satiety pathways, the pairing is a clean natural experiment — hold the GLP-1 arm constant, add amylin agonism, and watch what changes.
The bottom line
Cagrilintide and Semaglutide are not competitors in the usual sense. One is an amylin analogue, the other a GLP-1 agonist; they act on complementary satiety systems, which is precisely why the research field studies them together as CagriSema rather than one against the other. Semaglutide brings the deepest evidence base and an approved clinical pedigree; Cagrilintide brings a distinct, additive mechanism. For research-grade material, see our dedicated pages to buy Cagrilintide UK and buy Semaglutide UK — each ≥99% purity with a COA and free UK shipping.